Nonlinear QSAR and 3D QSAR

Similar documents
COMPUTER AIDED DRUG DESIGN (CADD) AND DEVELOPMENT METHODS

Structural biology and drug design: An overview

Chapter 8: Introduction to QSAR

Medicinal Chemistry/ CHEM 458/658 Chapter 3- SAR and QSAR

In silico pharmacology for drug discovery

International Journal of Research and Development in Pharmacy and Life Sciences. Review Article

Structure-Activity Modeling - QSAR. Uwe Koch

2. WATER : THE SOLVENT FOR BIOCHEMICAL REACTIONS

Plan. Day 2: Exercise on MHC molecules.

T. J. Hou, Z. M. Li, Z. Li, J. Liu, and X. J. Xu*,

5.1. Hardwares, Softwares and Web server used in Molecular modeling

Drug Design 2. Oliver Kohlbacher. Winter 2009/ QSAR Part 4: Selected Chapters

Last week, we discussed the Brønsted Lowry concept of acids and bases. According to this model:

Ligand-based QSAR Studies on the Indolinones Derivatives Bull. Korean Chem. Soc. 2004, Vol. 25, No

Drug Discovery. Zainab Al Kharusi Office: 33-10

Introduction to Chemoinformatics and Drug Discovery

Receptor Based Drug Design (1)

PHYSIO-CHEMICAL PROPERTIES OF THE DRUG. It is the interaction of the drug with its environment

Full file at Chapter 2 Water: The Solvent for Biochemical Reactions

ACIDS AND BASES. Note: For most of the acid-base reactions, we will be using the Bronsted-Lowry definitions.

16 years ago TODAY (9/11) at 8:46, the first tower was hit at 9:03, the second tower was hit. Lecture 2 (9/11/17)

A Review on Computational Methods in Developing Quantitative Structure-Activity Relationship (QSAR)

Aqueous solutions. Solubility of different compounds in water

3D-QSAR Studies on Angiotensin-Converting Enzyme (ACE) Inhibitors: a Molecular Design in Hypertensive Agents

CHEM 109A Organic Chemistry

Virtual screening for drug discovery. Markus Lill Purdue University

Docking. GBCB 5874: Problem Solving in GBCB

Statistical concepts in QSAR.

Solvent & geometric effects on non-covalent interactions

Introduction into Biochemistry. Dr. Mamoun Ahram Lecture 1

Molecular Modeling Study of Some Anthelmintic 2-phenyl Benzimidazole-1- Acetamides as β-tubulin Inhibitor

Chapter 2 Water: The Solvent for Biochemical Reactions

Molecular Interactions F14NMI. Lecture 4: worked answers to practice questions

Notes of Dr. Anil Mishra at 1

Overview. Descriptors. Definition. Descriptors. Overview 2D-QSAR. Number Vector Function. Physicochemical property (log P) Atom

Quiz QSAR QSAR. The Hammett Equation. Hammett s Standard Reference Reaction. Substituent Effects on Equilibria

Medicinal Chemistry/ CHEM 458/658 Chapter 4- Computer-Aided Drug Design

BIBC 100. Structural Biochemistry

Water, water everywhere,; not a drop to drink. Consumption resulting from how environment inhabited Deforestation disrupts water cycle

* Author to whom correspondence should be addressed; Tel.: ; Fax:

Using Bayesian Statistics to Predict Water Affinity and Behavior in Protein Binding Sites. J. Andrew Surface

Water: The Solvent for Biochemical Reactions

Acids and Bases. Moore, T. (2016). Acids and Bases. Lecture presented at PHAR 422 Lecture in UIC College of Pharmacy, Chicago.

Water. Water participates in H-bonding with biomolecules.

schematic diagram; EGF binding, dimerization, phosphorylation, Grb2 binding, etc.

Solutions and Non-Covalent Binding Forces

CHEM 4170 Problem Set #1

Molecular docking, 3D-QSAR studies of indole hydrazone as Staphylococcus aureus pyruvate kinase inhibitor

Ionization of acids and bases

Chemical properties that affect binding of enzyme-inhibiting drugs to enzymes

A primer on pharmacology pharmacodynamics

Hydrogen Bonding & Molecular Design Peter

Saba Al Fayoumi. Tamer Barakat. Dr. Mamoun Ahram + Dr. Diala Abu-Hassan

Description of Molecules with Molecular Interaction Fields (MIF)

SAR. Structure - Activity Relationships (alkoholy, amíny, aldehydy, ketóny, estery, amidy, kyseliny, uhľovodíky) 2/28/2016

Easier and Better Exploitation of PhysChem Properties in Medicinal Chemistry

Acid Base Equilibria

Acid-Base Properties

The following examination contains 31 questions valued at 3.5 points/question. Please use a ½ sheet green Scantron for questions 1-23.

Chapter 1. Introduction

ANSWERS TO CASE STUDIES Chapter 2: Drug Design and Relationship of Functional Groups to Pharmacologic Activity

ISSN: ; CODEN ECJHAO E-Journal of Chemistry 2009, 6(3),

Plan. Lecture: What is Chemoinformatics and Drug Design? Description of Support Vector Machine (SVM) and its used in Chemoinformatics.

Structural Bioinformatics (C3210) Molecular Mechanics

Quantum Mechanical Models of P450 Metabolism to Guide Optimization of Metabolic Stability

Other Cells. Hormones. Viruses. Toxins. Cell. Bacteria

Drug Design 2. Oliver Kohlbacher. Winter 2009/ QSAR Part I: Motivation, Basics, Descriptors

Similarity Search. Uwe Koch

Ping-Chiang Lyu. Institute of Bioinformatics and Structural Biology, Department of Life Science, National Tsing Hua University.

Lec.1 Chemistry Of Water

Carboxylic Acids and Nitriles

Chapter 1. Topic: Overview of basic principles

Water, ph and pka. Lecture 2: Margaret A. Daugherty. Fall Water: What makes it so good for life? Solvent properties.

Electronic Structure. Hammett Correlations. Linear Free Energy Relationships. Quantitative Structure Activity Relationships (QSAR)

QSAR Parameters. Hugo Kubinyi. What is QSAR? Germany. HomePage

Validation and Predictivity of QSAR Models

Chimica Farmaceutica

3D QSAR Analyses of Novel Tyrosine Kinase Inhibitors Based on Pharmacophore Alignment

Biophysics II. Hydrophobic Bio-molecules. Key points to be covered. Molecular Interactions in Bio-molecular Structures - van der Waals Interaction

Identification of Active Ligands. Identification of Suitable Descriptors (molecular fingerprint)

Principles of Drug Design

Biochemistry,530:,, Introduc5on,to,Structural,Biology, Autumn,Quarter,2015,

Biologically Relevant Molecular Comparisons. Mark Mackey

The ph of aqueous salt solutions

S2004 Methods for characterization of biomolecular interactions - classical versus modern

Welcome to Week 5. Chapter 9 - Binding, Structure, and Diversity. 9.1 Intermolecular Forces. Starting week five video. Introduction to Chapter 9

Quantitative Structure-Activity Relationship (QSAR) computational-drug-design.html

K w. Acids and bases 8/24/2009. Acids and Bases 9 / 03 / Ionization of water. Proton Jumping Large proton and hydroxide mobility

FORCES THAT DETERMINE LIGAND-RECEPTOR INTERACTIONS

LECTURE #25 Wed. April 9, 2008

Chemical and Physical Properties of Organic Molecules

Quantitative Structure-Activity Relationships : QSAR

Dihedral Angles. Homayoun Valafar. Department of Computer Science and Engineering, USC 02/03/10 CSCE 769

Chapter 20: Carboxylic Acids and Nitriles شیمی آلی 2

Acid-Base Chemistry & Organic Compounds. Chapter 2

Keywords: anti-coagulants, factor Xa, QSAR, Thrombosis. Introduction

3D QSAR studies of Substituted Benzamides as Nonacidic Antiinflammatory Agents by knn MFA Approach

MIDW 125 Math Review and Equation Sheet

Fondamenti di Chimica Farmaceutica. Computer Chemistry in Drug Research: Introduction

Retrieving hits through in silico screening and expert assessment M. N. Drwal a,b and R. Griffith a

Transcription:

onlinear QSAR and 3D QSAR Hugo Kubinyi Germany E-Mail kubinyi@t-online.de HomePage www.kubinyi.de onlinear Lipophilicity-Activity Relationships drug receptor Possible Reasons for onlinear Lipophilicity-Activity Relationships - kinetic control of drug transport in biological systems - equilibrium control of drug distribution - steric hindrance, allosteric effects - different pharmacokinetics and/or metabolism - solubility, micelle formation - end product inhibition of enzymes - drug receptor occupation

Parabolic Model (C. Hansch, 1964) log 1/C = a (log P) 2 + b log P + c log 1/C = a π 2 + b π + c log 1/C = a (log P) 2 + b log P + c σ + d log 1/C = a π 2 + b π + c σ + d E s + c, etc. Probability Model (J. McFarland, 1970) log 1/C = a log P - 2a log (P + 1) + c Equilibrium Model (R. Hyde, 1975) log 1/C = a log P - log (ap + 1) + c Bilinear Model (H. Kubinyi, 1976) log 1/C = a log P b log (ßP + 1) + c Hansch Multicompartment Model (1969) Definition P = k 1 /k 2 (correct) Hypothesis...... k 1.k 2 = 1 (wrong) 0 Log P

Hansch and Franke Models log 1/C = a log P + c (log P < log P x ) log 1/C = α (log P) 2 + ß log P + γ (log P > log P x ) McFarland Probability Model (1970) eurotoxic activity of alcohols, rat, i.p. application

Substance Distribution in a Three-Compartment System Rate constants of drug transport, k 1 and k 2 B. C. Lippold and G. F. Schneider, Arzneim.-Forsch. 25, 843 (1975) octanol phase B k 1 k 2 k 1 k 2 water phase A water phase C Homologous Quaternary -Alkylammoniumbromides, Water/n-ctanol/Water, + abr, experimental k 1 and k 2 values in h -1. umber of Carbon Atoms of Alkyl Group k 1 k 2 4 0.027 0.490 5 0.076 0.470 6 0.217 0.425 7 0.534 0.264 8 1.112 0.196 9 1.340 0.078 10 1.620 0.025 11 1.650 0.011

Bilinear Model log 1/C = a log P - b log (ßP + 1) + c Advantages of the bilinear model better fit of the linear left and right sides better description of the lipophilicity optimum Disadvantages of the bilinear model iterative estimation of the nonlinear parameter ß Loss of one degree of freedom (4 parameters, instead of 3)

eurotoxic Activity of Primary n-alcohols (rat, i.p. application) Log 1/C = 0.892 (±0.05) log P - 1.766 (±0.10) log (ßP + 1) - 1.586 log ß = - 1.933 log P optimum = 1.94 (n = 10; r = 0.996; s = 0.041; F = 637.6) onlinear Lipophilicity-Activity Relationships

Dissociation und Ionization HA A - n-octanol P u P i HA + H 2 A - + H 3 + K a aqueous buffer Henderson-Hasselbalch Equation [H 3 + ] = K a.(f u /f i ) ph = pk a + log (f i /f u ) = pk a + log f i - log f u f u = fraction of neutral form (undissoziated acid or base) f i = α = fraction of charged form (= 1 f u ) Dissociation of Acids and Ionization of Bases P app [AH] org [AH] aq + [A - ] aq = (1 - α ) P u = P u 1 + 10 ph - pk a Acids log P app = log P u - log (1 + 10 ph - pk a ) P app [B] org [BH + ] aq + [B ] aq = (1 - α) P u = P u 1 + 10 pk a - ph Bases log P app = log P u - log (1 + 10 pk a - ph )

Distribution of Acids, Bases and eutral Compounds CH H 1, Salicylic Acid pk a = 3.0 H 3 C CH 3 CH 3 HCCH 3 Et 2, Phenacetin neutral 4, Caffeine pk a = 0.6 S CH 3 H 3 C CH 3 3, Promethazine pk a = 9.1 Approximation for bases for ph > pk a log P app = log P u for ph < pk a log P app log P u - pk a + ph for ph << pk a log P app = log P i

Phe Phe n-butyl 1, Phenylbutazone pk a = 4.5 Phe Et H CH 3 Phe Phe H H 2, Diphenylhydantoin pk a = 8.3 CH 3, -Methylphenobarbital CCH pk a = 7.4 3 4, Acetylsalicylic Acid pk a = 3.5 Approximation for acids for ph < pk a log P app = log P u for ph > pk a log P app log P u ph + pk a for ph >> pk a log P app = log P i

ph Dependence of the Absorption of Acids and Bases A strong base like strychnine, pk a = 8.3, is not toxic for a dog with a pylorus ligation. Gastrointestinal Absorption of eutral Compounds and Acids a) eutral drug b) Acid, pk a = 4 Stomach, ph = 1 Blood circulation, ph = 7.4 HA HA A - A - Stomach, ph = 1 Blood circulation, ph = 7.4 Intestine, ph = 6-8 HA A - HA A - Intestine, ph = 6-8

Gastrointestinal Absorption of Weak and Strong Bases c) Weak base, pk a = 5 d) Strong base, pk a = 9 B B BH + B Stomach, ph = 1 BH + BH + B BH + Stomach, ph = 1 Blood circulation, ph = 7.4 Blood circulation, ph = 7.4 B B B B BH + BH + Intestine, ph = 6-8 BH + BH + Intestine, ph = 6-8 Buccal Absorption of Acids and Bases Compound ph log P app log k abs Propranolol -1.04-0.10-2.19-1.71 log P = 3.33 0.88-1.22 pk a = 9.45 1.81-0.79 2.70-0.53 3.21-0.35 p-hexylphenylacetic acid log P = 4.25 pk a = 4.36 5.08 6.02 7.00 7.93 8.94 9.93 4.00 5.00 6.00 7.00 8.00 9.00 4.20 3.63 2.72 1.72 0.72-0.28-0.46-0.54-0.72-1.07-1.44-1.78 log k abs = 0.45 (±0.05) log P app - 0.45 (±0.05) log (0.0016. P app + 1) - 1.69 (n = 12; r = 0.988; s = 0.102)

The ph Shift in the Absorption of Lipophilic Acids and Bases Distributed and absorbed amount of acid HA ph = ph absorption profile (kinetic control) ph partitioning profile (equilibrium) ph shift ph value 3D-QSAR Approaches CoMFA, Comparative Molecular Field Analysis (Richard Cramer et al., 1988) Select training and test sets of comparable diversity. Generate 3D structures of all molecules of the data set. Establish orientation rules for superposition of the molecules, using e.g. the "active analog approach". Align the molecules according to their pharmacophore and surface properties, using e.g. the program SEAL. Insert the molecules in a box and generate a grid that covers also a sufficiently large volume around the molecules.

Box and Grid CH CH 3 3 R Calculate property fields for every molecule, in each grid point, by using probe atoms or groups (steric and electrostatic effects are most often separately treated; in addition, hydrophobic effects as well as hydrogen bond donor and acceptor properties may be considered). Grid points with low variance may be neglected or variable / region selection can be performed. Perform PLS analysis, using an optimum number of latent variables (vectors) to correlate biological activities. Check the internal predictivity of the PLS model by a stepwise elimination of objects (crossvalidation). If necessary, repeat these steps. Predict the biological activities of the test set molecules.

Electrostatic, Steric and Similarity Fields Coulomb potential E C = n q q i i= 1 Dr j ij Lennard-Jones potential n vdw j ij 12 E = A r C j rij 6 i= 1 ( ) SEAL similarity coefficients m n AF wije r 2 = α ij ; w i = 1j = 1 ij = w E q i q j + w S v i v j +... E(r) Van-der-Waals potential, CoMFA (Lennard-Jones function) cut-off value CoMFA and CoMSIA Potentials Gaussian approximation, CoMSIA Coulomb potential, CoMFA (identical charges) 0 r

PLS (Partial Least Squares) Analysis X 1 From u = kt (k = constants k 1, k 2... k j ; j = number of PLS vektors) follows X 2 X 3 BA i = a 1 S i1 + a 2 S i2 + a 3 S i3 +... + a m S im + b 1 E i1 + b 2 E i2 + b 3 E i3 +... + b m E im Y vector BA 1 BA 2 BA 3 BA n S 11 S 12 S 13 S 21 S 22 S 23 S 31 S n1 S 32 S n2 X matrix S 33 S n3 S 14..... S 24..... S 34.......... S n4..... S 1m E 11 S 2m E 21 S 3 m S nm E 31 E n1 E 12..... E 22..... E 32.......... E n2..... E 1m E 2m E 3m E nm PLS analysis SAMPLS analysis u 11 u 12 u 13 t 11 t 12 t 13 u 1n,,... t 1n t 21 t 22 t 23 t 2n PLS vectors (latent variables) c 11 c 12 c 13...... c 1n c 21 c 22 c 23...... c 2n c 31 c 32 c 33...... c 3n...... c n1 c n2 c n3...... c nn covariance matrix

Steric CoMFA Contour Map Electrostatic CoMFA Contour Map

Recommendations for CoMFA Analyses ( good practice ) Type of biological data (affinities, inhibition constants) Variance and error range of biological data Selection of start geometries (flexible molecules) Method for calculation of charges should be cited Pharmacophore for superposition of the molecules Description of the alignment (atom-by-atom, field-based) Scaling and weighting of fields umber of PLS vectors ( ccam s razor ) Variable or region selection Crossvalidation - L or groups Crossvalidation only for internal prediction - Prediction of a test set! QSAR and 3D-QSAR, Scope and Limitations a) Free Wilson Analysis + easy to perform, most often unique solutions + clear separation of substituent effects + helps in the derivation of Hansch models + combination with Hansch analysis to a mixed approach - needs at least two sites of chemical variation - many parameters, only few degrees of freedom - very narrow QSAR models, no "outside" predictions

b) Hansch Analysis + correlates activities with physicochemical properties + "outside" predictions are possible - only applicable to congeneric series - works best with simple variation of aromatic substituents - considers only 2D structures - no unique solutions - risk of chance correlations (number of variables!) - risk of failure in "too far outside" predictions c) 3D QSAR (CoMFA and CoMSIA) + considers 3D structures of the ligands + applicable to more heterogeneous data sets + elektrostatic, steric, hydrophobic and hydrogen bond fields + 3D maps of favorable and unfavorable interactions - uncertainties about the bioactive conformation - uncertainties about different binding modes of ligands - cut-off levels (can be avoided in CoMSIA) - variable selection yields fragmented contour maps - high risk (if not guarantee) of chance correlations - only applicable to in vitro data